Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Michelle Meyer, Delphine C. Malherbe, Alexander Bukreyev

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

Original languageEnglish (US)
Pages (from-to)8-16
Number of pages9
JournalTrends in Microbiology
Issue number1
StatePublished - Jan 2019


  • Ebola
  • immune correlates
  • immunity
  • protection
  • vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Virology
  • Microbiology


Dive into the research topics of 'Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?'. Together they form a unique fingerprint.

Cite this